HomeCompareAGREE vs ALGN

AGREE vs ALGN: Dividend Comparison 2026

AGREE yields 4.00% · ALGN yields 1.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGREE wins by $6.6K in total portfolio value
10 years
AGREE
AGREE
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full AGREE calculator →
ALGN
ALGN
● Live price
1.20%
Share price
$166.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$130.06
Full ALGN calculator →

Portfolio growth — AGREE vs ALGN

📍 AGREE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGREEALGN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGREE + ALGN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGREE pays
ALGN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGREE
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
ALGN
Annual income on $10K today (after 15% tax)
$102.25/yr
After 10yr DRIP, annual income (after tax)
$110.55/yr
At 15% tax rate, AGREE beats the other by $653.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGREE + ALGN for your $10,000?

AGREE: 50%ALGN: 50%
100% ALGN50/50100% AGREE
Portfolio after 10yr
$24.7K
Annual income
$514.63/yr
Blended yield
2.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALGN right now

AGREE
No analyst data
ALGN
Analyst Ratings
24
Buy
7
Hold
2
Sell
Consensus: Buy
Price Target
$197.30
+18.7% upside vs current
Range: $140.00 — $220.00
Altman Z
4.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGREE buys
0
ALGN buys
0
No recent congressional trades found for AGREE or ALGN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGREEALGN
Forward yield4.00%1.20%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth5%0%
5-year div CAGR5%0%
Portfolio after 10y$28.0K$21.4K
Annual income after 10y$899.19$130.06
Total dividends collected$6.4K$1.3K
Payment frequencyquarterlyquarterly
SectorStockStock

Year-by-year: AGREE vs ALGN ($10,000, DRIP)

YearAGREE PortfolioAGREE Income/yrALGN PortfolioALGN Income/yrGap
1← crossover$11,120$420.00$10,820$120.29+$300.00AGREE
2$12,357$458.31$11,699$121.65+$658.00AGREE
3$13,721$499.76$12,641$122.92+$1.1KAGREE
4$15,227$544.58$13,650$124.13+$1.6KAGREE
5$16,885$593.02$14,731$125.27+$2.2KAGREE
6$18,713$645.34$15,889$126.34+$2.8KAGREE
7$20,724$701.81$17,128$127.36+$3.6KAGREE
8$22,938$762.73$18,455$128.31+$4.5KAGREE
9$25,372$828.41$19,876$129.21+$5.5KAGREE
10$28,047$899.19$21,398$130.06+$6.6KAGREE

AGREE vs ALGN: Complete Analysis 2026

AGREEStock

AGREE is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in AGREE shares.

Full AGREE Calculator →

ALGNStock

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Full ALGN Calculator →
📬

Get this AGREE vs ALGN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGREE vs SCHDAGREE vs JEPIAGREE vs OAGREE vs KOAGREE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.